<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="epcor-rice-rrdlbcl-cordoba">
    <meta name="study:title" content="S245 - First disclosure of Epcoritamab + R-ICE in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) eligible for autologous stem cell transplantation (ASCT): EPCORE NHL-2">
    <meta name="study:fileName" content="Abstracts/EPCOR-RICE-RRDLBCL-CORDOBA.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Epcoritamab,Bispecific antibodies,Rituximab,Monoclonal Antibody,Ifosfamide,Carboplatin,Etoposide,Chemotherapy,CIT,R-ICE">

    <title>S245: Epcoritamab + R-ICE in R/R DLBCL (Cordoba) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> </head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: S245 - Epcoritamab + R-ICE as Salvage Therapy in R/R DLBCL for ASCT Eligibility (EPCORE NHL-2)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996 2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=31)</h4>
                    <p>R/R DLBCL Pts, ASCT-eligible, ≥1 prior LOT. Aim: Evaluate efficacy & safety of Epcoritamab + R-ICE.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention</h4>
                    <p>Epcoritamab 48mg (step-up C1, QW C1-4, Q2W C5-9, Q4W C10+) + R-ICE (C1-3). Median 4 epcor, 3 R-ICE cycles.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (N=31)</h4>
                    <p>ORR: <span class="highlight-value">87%</span> (CR 65%, PR 23%). 65% proceeded to ASCT. 6mo: 81% DOR, 74% PFS, 100% OS.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Manageable. CRS 52% (all G1/2). Neutropenia 74%. No G5 TEAEs. Optimizes salvage, increases ASCT eligibility.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">S245 - First disclosure of Epcoritamab + R-ICE in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) eligible for autologous stem cell transplantation (ASCT): EPCORE NHL-2</h1>
            <p class="abstract-sub-header">Raul Cordoba, Marek Trneny, Sven De Vos, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #S245 | Oral Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>~50% of LBCL patients (pts) are refractory to salvage chemoimmunotherapy (CIT) like R-ICE.</li>
                        <li>Unmet need to optimize salvage therapy (tx) to increase complete response (CR) rates and ASCT eligibility.</li>
                        <li>CAR-T is an alternative, but challenges (logistics, cost, access, durability) remain.</li>
                        <li>Epcoritamab (epcor), a subcutaneous CD3xCD20 bispecific antibody, showed high CR rates with R-DHAX/C.</li>
                        <li>This is the first report of epcor + R-ICE in R/R DLBCL pts eligible for ASCT (EPCORE NHL-2 trial, NCT04663347).</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Trial: EPCORE NHL-2 (Phase 1/2).</li>
                        <li>Patients: R/R DLBCL, eligible for R-ICE and ASCT, ≥1 prior line of tx (LOT).</li>
                        <li>Treatment Regimen:
                            <ul class="list-circle list-inside ml-4">
                                <li>Epcoritamab 48 mg SC: Step-up doses C1 (0.16mg, 0.8mg), then full dose QW C1-4; Q2W C5-9; Q4W C10+.</li>
                                <li>R-ICE: Standard doses for Cycles 1-3.</li>
                                <li>Cycle Length: C1-4 (21 days), C5+ (28 days).</li>
                            </ul>
                        </li>
                        <li>Treatment Duration: Until ASCT, progressive disease (PD), or unacceptable toxicity.</li>
                        <li>Primary Endpoint: Overall Response Rate (ORR) per investigator (Lugano criteria).</li>
                        <li>Data Cutoff: Dec 18, 2024. Median follow-up: 11 months (range, 6-15).</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">EPCORE NHL-2: Epcoritamab + R-ICE Regimen</h3>
                        <div class="schema-enrollment">
                            <strong>Eligible Pts (N=31 analyzed)</strong>
                            <span>R/R DLBCL, ASCT-eligible, ≥1 prior LOT</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase">
                                <strong>Induction (Cycles 1-3)</strong>
                                <span>Epcoritamab 48mg SC (step-up C1, then QW)</span>
                                <span>+ R-ICE (standard)</span>
                            </div>
                        </div>
                         <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                             <div class="schema-phase">
                                <strong>Epcoritamab Continuation (Post R-ICE)</strong>
                                 <span>C4: QW</span>
                                 <span>C5-9: Q2W</span>
                                 <span>C10+: Q4W</span>
                                 <span>(Until ASCT, PD, or toxicity)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                         <div class="schema-phase-group">
                            <div class="schema-phase" style="background-color: var(--sobi-light-teal-bg);">
                                <strong>ASCT</strong>
                                <span>For eligible responders</span>
                            </div>
                        </div>
                        <div class="schema-assessment-points">
                           <span>Primary Endpoint: ORR (Lugano)</span>
                           <span>Secondary: CR, DOR, PFS, OS, Safety (TEAEs, CRS, ICANS)</span>
                        </div>
                    </div>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=31)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Median Age: 62 years (range, 39-77).</li>
                        <li>Male: 55%.</li>
                        <li>Ann Arbor Stage III/IV: 61%.</li>
                        <li>Bulky Disease (≥7 cm): 42%.</li>
                        <li>Prior Lines of Therapy (LOT): 81% had 1 prior LOT (range, 1-3).</li>
                        <li>Progressed within 12 months of 1L tx: 65% (high-risk).</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (N=31, Epcor 48mg + R-ICE)</h2>
                    <p class="text-sm mb-2">Median initiated tx cycles: Epcor 4 (range, 2-14); R-ICE 3 (range, 2-3).</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>Overall Response Rate (ORR): 87% (27/31)</strong></li>
                        <li>Complete Response (CR): 65% (20/31)</li>
                        <li>Partial Response (PR): 23% (7/31)</li>
                        <li>High ORR and CR rates observed across subgroups of interest (see Table).</li>
                    </ul>
                    <div class="abstract-card mt-4">
                        <h3 class="text-md font-semibold mb-2 text-center" style="color: var(--sobi-dark-blue);">Table: ORRs and CR rates with epcor + R-ICE</h3>
                        <img src="uploaded:image_ae3fef.png-48ac71ea-f52e-4141-884c-2c304a87ce43" alt="Table of ORR and CR rates" class="mx-auto rounded-lg shadow-md" style="max-width: 100%; height: auto;" onerror="this.onerror=null;this.src='https://placehold.co/600x200/EBF4FA/1E3A8A?text=Table+Not+Available';">
                         <p class="text-xs text-center mt-2 italic">Table: ORRs and CR rates with epcor + R-ICE in pts with R/R DLBCL.</p>
                    </div>
                     <p class="text-sm font-semibold mt-3 mb-1">Autologous Stem Cell Transplant (ASCT):</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Proceeded to ASCT: 65% (20/31 pts).
                            <ul class="list-circle list-inside ml-4">
                                <li>Pre-ASCT status: 13 CR, 7 PR.</li>
                                <li>Post-ASCT: 5 of 7 PRs converted to CR.</li>
                            </ul>
                        </li>
                        <li>Did not proceed to ASCT (n=11):
                            <ul class="list-circle list-inside ml-4">
                                <li>3 (10%) remained on epcor (1 CR, 2 PR).</li>
                                <li>8 (26%) discontinued (6 PD, 2 other). 6 of these received subsequent tx (3 CAR-T).</li>
                            </ul>
                        </li>
                    </ul>
                    <p class="text-sm font-semibold mt-3 mb-1">Survival Estimates (at 6 months):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Duration of Response (DOR): 81% of responses ongoing.</li>
                        <li>Progression-Free Survival (PFS): 74% of pts progression-free.</li>
                        <li>Overall Survival (OS): 100% of pts alive.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary (N=31)</h2>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>Most Common TEAEs (any grade):</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>Neutropenia: 74%</li>
                                <li>Anemia: 68%</li>
                                <li>Thrombocytopenia: 68%</li>
                            </ul>
                        </li>
                        <li>Cytokine Release Syndrome (CRS): 52% (all Grade 1/2, all resolved).</li>
                        <li>Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): 1 pt (Grade 1, resolved).</li>
                        <li>Clinical Tumor Lysis Syndrome: None observed.</li>
                        <li>Infections: 58% (18 pts); Serious infections: 16% (5 pts).</li>
                        <li>No discontinuations of epcoritamab due to TEAEs.</li>
                        <li>No Grade 5 TEAEs reported.</li>
                    </ul>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>Epcoritamab + R-ICE demonstrated high CR rates (65%) and ORR (87%) in ASCT-eligible R/R DLBCL patients, including a high-risk population (65% progressed <12 mo of 1L tx).</li>
                <li>The safety profile was manageable, with low-grade CRS and no discontinuations due to AEs.</li>
                <li>A high proportion of patients (65%) were able to proceed to ASCT.</li>
                <li>These results suggest that epcoritamab combined with CIT may optimize salvage therapy, potentially increasing ASCT eligibility and offering a greater chance of cure compared to historical rates.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>1L, First Line; AE, Adverse Event; ASCT, Autologous Stem Cell Transplantation; C, Cycle; CAR-T, Chimeric Antigen Receptor T-cell; CIT, Chemoimmunotherapy; CR, Complete Response; CRS, Cytokine Release Syndrome; DLBCL, Diffuse Large B-Cell Lymphoma; DOR, Duration of Response; Epcor, Epcoritamab; G, Grade; ICANS, Immune Effector Cell-Associated Neurotoxicity Syndrome; LOT, Line of Therapy; NHL, Non-Hodgkin Lymphoma; ORR, Overall Response Rate; OS, Overall Survival; PD, Progressive Disease; PFS, Progression-Free Survival; PR, Partial Response; Pt(s), Patient(s); QW, Once Weekly; Q2W, Once Every 2 Weeks; Q4W, Once Every 4 Weeks; R-DHAX/C, Rituximab, Dexamethasone, Cytarabine, Oxaliplatin or Carboplatin; R-ICE, Rituximab, Ifosfamide, Carboplatin, Etoposide; R/R, Relapsed/Refractory; SC, Subcutaneous; SCT, Stem Cell Transplant; TEAE, Treatment-Emergent Adverse Event; Tx, Therapy; y, Years.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Cordoba R, Trneny M, De Vos S, et al. First disclosure of Epcoritamab + R-ICE in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) eligible for autologous stem cell transplantation (ASCT): EPCORE NHL-2. Abstract #S245 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #S245 | Abstract Release: 05/14/2025 | Presentation: 06/15/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div> <script defer src="abstract_features.js"></script>
    </body>
</html>
